-The Hindu     Enhancing the basket of contraceptive choices can reduce maternal mortality rate, says a family planning review Family planning has made a silent comeback in the national discourses. This time, focussing more on concomitant improvement in the health of the people rather than limiting the number of children. India had changed its strategy on family planning in 2010 with the other developing countries from that of merely reducing population to that of...

-The Hindu   Even after five decades of feminism and female participation in the productive economy, the problem of women falling off the organised workforce remains a global phenomenon Former Lehman Brothers Chief Financial Officer Erin Callan recently urged women not to work too hard at their professions. Her comments in The New York Times about the dangers of losing the work-life balance came on the eve of the publication of Facebook COO...

-The Hindu The Supreme Court has denied Novartis a patent for its anti-cancer drug Gleevec. This leaves the door open for Indian pharmaceutical companies to produce their own versions of the drug. Since these are sold at roughly one tenth of the patented brand price, for thousands of cancer patients it means the difference between medicine and no medicine at all. It is not just cancer patients that will benefit, but...

-The Economic Times MUMBAI: India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that...

-The Economic Times WASHINGTON: Big Pharma found little support from the small guy on the street as the Indian Supreme Court's decision to reject patent claims of the drug maker Novartis for its celebrated cancer medicine Glivec reverberated across the world. The pharma lobby railed against the decision but the overwhelming sentiment, from physicians to politicians, from academia to media, particularly in a country groaning from the high cost of health care,...